The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
It promises fewer injections for vision loss patients
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Subscribe To Our Newsletter & Stay Updated
